CD14 and Cognitive impairment: Thus, the potential to prevent infectious replication-competent or replication-defective virus from entering the CNS through blocking the entry of HIV+ CD14+ CD16+ monocytes by targeting their JAM-A and CCR2, and potentially ALCAM, may be a new area to examine in aiming to eliminate viral seeding and replenishment, as well as to reduce the neuroinflammation and neuronal damage that contribute to cognitive deficits.